News Focus
News Focus
Followers 44
Posts 1261
Boards Moderated 0
Alias Born 06/09/2020

Re: Mr.reveulto post# 798398

Wednesday, 11/19/2025 8:46:12 AM

Wednesday, November 19, 2025 8:46:12 AM

Post# of 821329
$NWBO Northwest Biotherapeutics has submitted a Marketing Authorization Application (MAA) to the MHRA for DCVax®-L, an immunotherapy for glioblastoma. The MHRA are unable to comment on applications during the process of review, but the MHRA can CONFIRM that this application is NOT AFFECTED BY ANY BACKLOGS.
Here we go again with the BIZARRE “confirmation” that the delay in reviewing the DCVAX-l MAA IS NOT AFFECTED BY ANY BACKLOGS.
This is code for it’s NOT our fault. meaning something about the MAA status CHANGED between 12/11/2023 & 3/31/2025.
Bears will say the MAA was one of the few with major issues referred to CHM
Bulls will say that the MAA was modified to include something positive like Flaskworks, ORBIS, or agnostic.
I actually lean towards the former but in light of the advent news, Dr ashkan’s 2 month estimate, and GZ’s email to Lefty49 on IHUB, I still believe the MAA will be approved this year. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176939596
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News